Orion published Interim Report for January-September 2019 on Wednesday 23 October 2019.
|11/4/2019||125,000 Orion Corporation A shares converted into B shares|
|10/28/2019||Composition of the Nomination Committee of Orion Corporation|
|10/23/2019||Orion Group Interim Report 1–9/2019|
|9/2/2019||135,000 Orion Corporation A shares converted into B shares|
|11/4/2019||Orion Research Foundation grants 902 000 euros for research in 2020|
|10/7/2019||Publishing of Orion Corporation's Interim Report for January-September 2019 on 23 October 2019|
|9/10/2019||Orion recalls Melatoniini Orion 1 mg Spray 20 ml oral spray from consumers|
|8/7/2019||Sales of darolutamide started in the USA – Orion receives EUR 45 million milestone|
The product and service portfolio of Orion includes a variety of human pharmaceuticals, veterinary drugs, APIs and contract manufacturing.
Orion’s pharmaceutical innovations are created within its R&D organisation. The organisation employs top professionals in the field of drug molecule development and optimisation.
One key area of Orion's business is Critical Care. Our portfolio includes Simdax® for acute heart failure and Precedex® and Dexdor® for sedation. Read more about Orion's proprietary products and other human pharmaceuticals.
Orion is the largest employer in the Finnish pharmaceutical industry. It is considered to be a good and reliable employer, which is also indicated by its lower-than-average employee turnover.